SCHEMBL12420227

SCHEMBL12420227

CCCCCN1C(=O)c2ccc(B(O)O)cc2C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.48
▸ ALDH1A1 P00352 10/20 0.47
▸ HSD17B10 Q99714 3/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ HTT P42858 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ RECQL P46063 2/20 0.44
▸ RGS12 O14924 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ PABPC1 P11940 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ CASP1 P29466 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CASP7 P55210 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16832060 0.83 POLB (0.57) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2665904 0.78 CHRM2 (0.64) KDM4ENPC1RAB9ACHRM2
SCHEMBL11878800 0.77 HSD17B10 (0.64) KDM4EALDH1A1HSD17B10MAPK1MEN1
SCHEMBL8660199 0.77 KDM4E (0.47) KDM4EALDH1A1HSD17B10MAPK1MEN1
SCHEMBL8658770 0.77 ALDH1A1 (0.62) KDM4EALDH1A1HSD17B10MAPK1MEN1
SCHEMBL13159367 0.77 ALDH1A1 (0.71) ALDH1A1HSD17B10MAPK1MEN1KMT2A
SCHEMBL10451307 0.76 ACHE (0.49) KDM4EALDH1A1MEN1KMT2ATSHR
SCHEMBL14560519 0.76 HSD17B10 (0.62) KDM4EALDH1A1HSD17B10MAPK1MEN1
SCHEMBL12979075 0.76 ALDH1A1 (0.60) KDM4EALDH1A1HSD17B10MAPK1MEN1
SCHEMBL2892202 0.76 CNR2 (0.50) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 — — US disclosed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 — — US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 — — US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 — — US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 — — US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 — — US disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 KDM4E 1442/4885ALDH1A1 354/4885HSD17B10 93/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 KDM4E 1442/4885ALDH1A1 354/4885HSD17B10 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback